RxDoctor Payments Data

Michael Higgins, MD

Internal Medicine · Norfolk, MANPI 1730251661

Payments from drug & device makers

$2,604in general payments, 2019–2025

Across 131 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$406
  • AstraZeneca$197
  • Pfizer$184
  • Stryker$173
  • Amgen$170
  • Novo Nordisk$169
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,604 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$129,449
Medicare patients
301
Services billed
2,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$91,425
JardianceEmpagliflozin73$74,394
OzempicSemaglutide41$39,777
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,026
Breo ElliptaFluticasone/Vilanterol16$8,528
TrintellixVortioxetine Hydrobromide12$6,721
Atorvastatin Calcium449$6,118
BelsomraSuvorexant12$5,058
Metoprolol Succinate192$3,917
Omeprazole196$3,410
SynthroidLevothyroxine Sodium30$2,984
Amlodipine Besylate314$2,545
Levothyroxine Sodium273$2,486
Pravastatin Sodium64$2,444
Rosuvastatin Calcium144$2,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$184$91,425112 claims
Boehringer IngelheimJardiance$106$74,39473 claims
Novo NordiskOzempic$169$39,77741 claims
AstraZenecaBreztri Aerosphere$197$9,02614 claims
GSKBreo Ellipta$38$8,52816 claims
MerckBelsomra$133$5,05812 claims
AbbVieSynthroid$61$2,98430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Norfolk

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →